GO:0009086 obsolete methionine biosynthetic process

The Gene Ontology (GO) term GO:0009086, obsolete methionine biosynthetic process, was historically used to annotate the chemical reactions and pathways resulting in the de novo formation of L-methionine (2-amino-4-(methylthio)butanoic acid), a sulfur-containing essential amino acid found in peptide linkage in proteins. Methionine biosynthesis is a central metabolic pathway in many microorganisms and plants, where it serves as a precursor for proteins, S-adenosylmethionine (SAM), and other sulfur-containing metabolites. In humans, the pathway is absent, and methionine must be obtained from the diet, although it can be regenerated through the methionine cycle. The obsoletion of this term reflects the ongoing refinement of the Gene Ontology to avoid redundancy and to promote the use of more precise terms that capture the specific enzymatic steps and subpathways involved. Despite its obsolete status, the biological process it described remains a topic of active research, particularly in the context of infectious diseases, cancer metabolism, and plant biology. Understanding the genes and enzymes involved in methionine biosynthesis is essential for developing novel antimicrobials, herbicides, and for engineering crops with improved nutritional value. This article provides a comprehensive overview of the obsolete term, its definition, the key genes and proteins involved, and the research methods used to study this fundamental pathway.

GO:0009086, obsolete methionine biosynthetic process, was defined as the chemical reactions and pathways resulting in the de novo formation of L-methionine (2-amino-4-(methylthio)butanoic acid), a sulfur-containing, essential amino acid found in peptide linkage in proteins. This definition encompasses the enzymatic steps that convert simpler precursors, such as homoserine or cysteine, into methionine, often involving the transfer of a methyl group and the incorporation of sulfur. The term was classified under the biological_process ontology aspect and had synonyms including methionine anabolism, methionine biosynthesis, methionine formation, and methionine synthesis. It has since been made obsolete because the GO Consortium determined that the process is better represented by more specific terms that describe the individual reactions and subpathways, such as those for the transsulfuration pathway or the direct sulfhydrylation pathway. Researchers should now use these more granular terms for annotation purposes, but the historical term remains useful for understanding the broader context of methionine metabolism.

Although GO:0009086 is obsolete, the biological process it described remains critically important because methionine biosynthesis is essential for the survival of many pathogenic microorganisms and is a key determinant of nutritional quality in crops. In humans, methionine is an essential amino acid, and its metabolism is tightly linked to methylation, redox balance, and polyamine synthesis; dysregulation of these processes contributes to cancer, cardiovascular disease, and neurological disorders. The enzymes of the methionine biosynthetic pathway are attractive targets for antibiotics and herbicides because they are absent in humans, offering selective toxicity. Furthermore, understanding the pathway is vital for metabolic engineering of microorganisms for industrial production of methionine and related compounds. Thus, even as an obsolete GO term, it serves as a useful entry point for researchers exploring sulfur amino acid metabolism.

The following genes and proteins are key players in the methionine biosynthetic process, as documented in the literature.

The obsolete methionine biosynthetic process is regulated by a complex network of transcriptional, translational, and post-translational mechanisms. In bacteria such as Escherichia coli, the MetJ repressor binds to the promoter regions of methionine biosynthesis genes in the presence of S-adenosylmethionine (SAM), which acts as a corepressor. The MetR activator, on the other hand, stimulates transcription in response to homocysteine. In Bacillus subtilis, the S-box riboswitch in the 5' untranslated region of methionine biosynthesis genes binds SAM and terminates transcription when methionine levels are high. In yeast, the transcription factor Met4 is activated by the absence of methionine and regulates a large regulon of sulfur amino acid metabolism genes; its activity is controlled by the SCF-Met30 ubiquitin ligase complex. In plants, methionine biosynthesis is regulated by developmental cues and sulfur availability, with enzymes such as cystathionine gamma-synthase being subject to feedback inhibition by SAM. Additionally, the pathway is integrated with the methionine cycle and the folate cycle, which provide the methyl groups for homocysteine methylation.

Many pathogenic bacteria, such as Mycobacterium tuberculosis, Staphylococcus aureus, and Pseudomonas aeruginosa, rely on de novo methionine biosynthesis for survival and virulence. The enzymes of this pathway are absent in humans, making them attractive targets for the development of new antibiotics. For example, inhibitors of cystathionine beta-lyase have shown antibacterial activity against M. tuberculosis. The obsolete GO term GO:0009086 historically annotated these processes, and research into the pathway continues to inform drug discovery.

In cancer cells, methionine metabolism is often reprogrammed to support rapid proliferation. Although humans cannot synthesize methionine de novo, cancer cells can become dependent on exogenous methionine, a phenomenon known as methionine dependence or the Hoffman effect. This has led to the development of methionine-restricted diets and methioninase-based therapies as potential anticancer strategies. The enzymes of the methionine cycle, such as methionine synthase and methylenetetrahydrofolate reductase, are also implicated in cancer risk and progression. The obsolete term GO:0009086 is not directly used in cancer research, but the pathway it described is relevant to understanding methionine dependence.

In plants, methionine is an essential amino acid for human and animal nutrition, and its biosynthesis is a target for crop improvement. Engineering the methionine biosynthetic pathway in crops such as maize and soybean can increase nutritional value. The pathway is also involved in plant defense responses and stress tolerance. The obsolete GO term GO:0009086 has been used to annotate plant genes involved in methionine biosynthesis, although more specific terms are now recommended.

Disruptions in methionine metabolism, including the methionine cycle and transsulfuration, have been linked to neurological disorders such as Alzheimer's disease, Parkinson's disease, and schizophrenia. Elevated homocysteine levels, a marker of impaired methionine metabolism, are associated with cognitive decline and neurodegeneration. Although de novo methionine biosynthesis does not occur in humans, the enzymes involved in the methionine cycle are relevant to these conditions. The obsolete GO term GO:0009086 serves as a historical reference for the broader pathway.

Classical genetic screens and targeted gene knockouts have been instrumental in identifying the genes involved in methionine biosynthesis. In bacteria, transposon mutagenesis and deletion libraries have been used to map the pathway. In yeast, the systematic deletion of all non-essential genes has provided a comprehensive view of methionine metabolism. These approaches are complemented by CRISPR-Cas9 genome editing, which allows precise knockout and knock-in of pathway genes in various organisms.

Enzymatic activities of methionine biosynthetic enzymes can be measured using coupled assays that monitor the formation of products such as homocysteine or methionine. For example, methionine synthase activity is often assayed by measuring the conversion of homocysteine to methionine using a radioactive or fluorescent substrate. Cystathionine beta-lyase activity can be measured by monitoring the cleavage of cystathionine to homocysteine and pyruvate. These assays are essential for characterizing mutant enzymes and for high-throughput screening of inhibitors.

Metabolomics approaches, such as liquid chromatography-mass spectrometry (LC-MS), allow the quantification of intracellular metabolites in the methionine biosynthetic pathway. Stable isotope labeling with 13C or 15N can be used to trace metabolic fluxes through the pathway. These methods have been used to study the regulation of methionine biosynthesis in response to environmental changes. Flux balance analysis combined with genome-scale metabolic models can predict the impact of gene deletions on methionine production.

RNA sequencing (RNA-seq) and microarray analysis have been used to identify genes that are differentially expressed under conditions of methionine limitation or excess. Chromatin immunoprecipitation sequencing (ChIP-seq) can map the binding sites of transcription factors such as MetJ and Met4. Proteomics approaches, including mass spectrometry-based quantification, can measure the abundance of methionine biosynthetic enzymes and their post-translational modifications. These techniques provide a systems-level view of pathway regulation.

Researchers studying obsolete methionine biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in methionine metabolism, whether a specific mutation alters enzyme function, or whether overexpression can enhance pathway flux. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions, from gene knockout to precise point mutations and knock-ins, enabling rigorous functional studies in any organism.

GO:0009086, obsolete methionine biosynthetic process, represents a fundamental metabolic pathway that, although no longer active in the Gene Ontology, remains a vibrant area of research. The pathway is essential for microorganisms and plants, and its absence in humans makes it a promising target for antimicrobials and herbicides. Dysregulation of methionine metabolism is implicated in a range of human diseases, from cancer to neurodegeneration. By leveraging CRISPR-based tools and advanced omics technologies, researchers can continue to unravel the complexities of this pathway and translate findings into therapeutic and biotechnological applications. EDITGENE is committed to supporting this research with high-quality gene editing models and services.